semaglutide ohio Ozempic® (semaglutide) GLP-1 RA for Type 2 Diabetes Ohio to tighten oversight of

Commonly reported side effects include: Nausea, vomiting, and diarrhoea particularly during dose escalation Constipation and abdominal discomfort Decreased appetite and early satiety Injection site reactions (mild and transient) Fatigue, especially in the initial weeks of treatment These gastrointestinal effects are consistent with the GLP-1 mechanism and are generally dose-dependent and transient

Drug pipeline 2016

GLP-1 receptor agonists are well-established for their appetite-suppressing effects, which contribute significantly to their weight loss benefits

Group 6 maintained a maximum activity from day 7 to day 30